Floatz logo

Doxycycline

B-Cell Chronic Lymphocytic Leukemia

Janssen Research & Development, LLCSmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the B-Cell Chronic Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
CHLORAMBUCIL
Janssen Research & Development, LLC
Phase 3BB
C-Car066
National Cancer Institute (NCI)
Phase 2BB
PENTOSTATIN
Heidelberg University
Phase 3BB
Campath
Genzyme, a Sanofi Company
Phase 3B
Bafetinib
CytRx
Phase 2B

View all 17 →

Same molecule, other indications

Doxycycline is also rated in:

lymphangioleiomyomatosisDormant
BB
Indicative ·
64 / 100
View asset →
tuberous sclerosisDormant
BB
Indicative ·
64 / 100
View asset →
Chronic Pelvic Pain SyndromeDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →